Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the preventive treatment of migraine. DrugPatentWatch.com tracks patents related to drugs like atogepant. [1]
What is the atogepant spiro patent?
The term "atogepant spiro patent" likely refers to patents covering the chemical structure of atogepant, which includes a spirocyclic moiety. Patents for pharmaceutical compounds are crucial for protecting the intellectual property of the drug's developer and ensuring market exclusivity. [1]
When does atogepant's patent protection expire?
Patent expiration dates determine when generic versions of a drug can enter the market. Information on specific patent expiration dates for atogepant can be found through patent databases and specialized resources like DrugPatentWatch.com, which monitors patent lifecycles for pharmaceutical products. [1]
Who developed atogepant?
Atogepant was developed by AbbVie. [2]
How does atogepant work for migraine prevention?
Atogepant targets the CGRP pathway, which plays a significant role in migraine pathophysiology. By blocking the CGRP receptor, it is believed to prevent the vasodilation and neuroinflammation associated with migraine attacks. [3]
What is the difference between atogepant and other CGRP inhibitors?
Atogepant is an oral CGRP receptor antagonist. Other CGRP-targeting medications include gepants (also oral CGRP receptor antagonists like rimegepant and ubrogepant) and monoclonal antibodies that target the CGRP ligand or its receptor. Atogepant is specifically indicated for migraine prevention, while some other CGRP inhibitors are approved for both acute treatment and prevention. [3, 4]
Can generic atogepant be produced before patent expiry?
Generally, generic versions of a drug cannot be legally manufactured or marketed until the relevant patents have expired or been successfully challenged. Companies seeking to produce generics will typically wait for patent expiration or engage in patent litigation to invalidate existing patents. [1]
What are the clinical trial results for atogepant?
Clinical trials have demonstrated that atogepant significantly reduces monthly migraine days compared to placebo. For example, in the ADVANCE trial, patients treated with atogepant experienced a greater reduction in mean monthly migraine days. [3]
What are the potential side effects of atogepant?
Common side effects reported in clinical trials include upper respiratory tract infection, nausea, and fatigue. [3]
How is atogepant administered?
Atogepant is taken orally, typically once daily. [3]
What is the pricing of atogepant?
Pricing information for atogepant can vary by region and insurance coverage. Patients and healthcare providers often consult drug pricing resources or contact the manufacturer for specific cost details.
Where can I find more information on atogepant patents?
For detailed information on atogepant's patent landscape, including specific patent numbers and expiration dates, DrugPatentWatch.com is a valuable resource. [1]
Sources:
[1] DrugPatentWatch.com
[2] AbbVie. Atogepant. https://www.abbvie.com/our-science/pipeline/atogepant.html
[3] Edvinsson L. CGRP receptor antagonists in migraine treatment. Nat Rev Neurol. 2021;17(5):291-304. doi: 10.1038/s41582-021-00458-5.
[4] Ghiasi MS, et al. Calcitonin Gene-Related Peptide (CGRP) Pathway: Role in Migraine Pathophysiology and Treatment. Curr Pain Headache Rep. 2017;21(5):23. doi: 10.1007/s11916-017-0622-3.